Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 2/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.47 |
| ▸ | F7 | P08709 | 1/20 | 0.46 |
| ▸ | F3 | P13726 | 1/20 | 0.46 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL404854 | 0.89 | NR4A2 (0.60) | NR4A2F7F3 | |
| SCHEMBL6334125 | 0.85 | NR4A2 (0.74) | NR4A2F7F3MAPT | |
| SCHEMBL22445235 | 0.84 | GABRA1 (0.56) | NR4A2MAPT | |
| SCHEMBL30539775 | 0.84 | GABRA1 (0.56) | NR4A2MAPT | |
| SCHEMBL1557626 | 0.84 | ALDH1A1 (0.47) | NR4A2MAPT | |
| SCHEMBL1557688 | 0.83 | MAPT (0.64) | NR4A2ALOX15MAPT | |
| SCHEMBL1559282 | 0.81 | MEN1 (0.54) | NR4A2 | |
| SCHEMBL29790938 | 0.80 | GABRA1 (0.58) | NR4A2MAPT | |
| SCHEMBL368012 | 0.80 | GABRA1 (0.58) | NR4A2MAPT | |
| SCHEMBL30906938 | 0.80 | GABRA1 (0.63) | NR4A2ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1662255-A2 | Homer interacting proteins | THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE (US) | 2006-05-31 | — | — | EP | claimed |
| US-7446122-B2 | Substituted indole derivatives | CEPHALON, INC. (US) | 2008-11-04 | — | — | US | disclosed |
| US-7378498-B2 | Metabotropic glutamate receptor regulator for use in identifying modulator of channel-mediated intracellular calcium mobilization and treatment of nervous system disorders | THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE (US) | 2008-05-27 | — | — | US | disclosed |
| US-7314886-B2 | Tetrahydropyrano-indole derivatives | CEPHALON, INC. (US) | 2008-01-01 | — | — | US | disclosed |
| US-20070244180-A1 | Substituted indole derivatives | SALMEDIX, INC. | 2007-10-18 | — | — | US | disclosed |
| US-20060166947-A1 | Multiple myeloma treatments | DANA-FARBER CANCER INSTITUTE, INC. | 2006-07-27 | — | — | US | disclosed |
| US-20060160876-A1 | (6-Bromo-1,8-diethyl-1,3,4,9-tetrahydro-pyrano[3,4-b]indol-1-yl)-acetic acid ethyl ester; antineoplastic, anti-inflammatory, analgesic | SALMEDIX, INC. | 2006-07-20 | — | — | US | disclosed |
| EP-1680428-A2 | SUBSTITUTED INDOLE DERIVATIVES | CEPHALON, INC. (US) | 2006-07-19 | — | — | EP | disclosed |
| EP-1673373-A2 | INDOLE DERIVATIVES | Salmedix, Inc. (US) | 2006-06-28 | — | — | EP | disclosed |
| EP-1662255-A2 | Homer interacting proteins | THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE (US) | 2006-05-31 | — | — | EP | disclosed |
| US-20050164344-A1 | Nucleic acid molecule encoding homer 1B protein | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-07-28 | — | — | US | disclosed |
| WO-2005033112-A2 | SUBSTITUTED INDOLE DERIVATIVES | CEPHALON, INC. (US) | 2005-04-14 | — | — | WO | disclosed |
| WO-2005033113-A2 | INDOLE DERIVATIVES | CEPHALON, INC (US) | 2005-04-14 | — | — | WO | disclosed |
| EP-1105734-A4 | HOMER INTERACTING PROTEINS | UNIV JOHNS HOPKINS MED (US) | 2005-04-13 | — | — | EP | disclosed |
| US-6864083-B2 | Nucleic acid molecule encoding homer 2a protein | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-03-08 | — | — | US | disclosed |
| US-6720175-B1 | MEDIATING RECEPTOR-ACTIVATED OR ION CHANNEL-MEDIATED INTRACELLULAR CALCIUM MOBILIZATION OR CONCENTRATION. | THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE | 2004-04-13 | — | — | US | disclosed |
| US-20030170807-A1 | Nucleic acid molecule encoding homer 1b protein | THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE | 2003-09-11 | — | — | US | disclosed |
| EP-1105734-A2 | HOMER INTERACTING PROTEINS | THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE (US) | 2001-06-13 | — | — | EP | disclosed |
| WO-2000011204-A2 | HOMER INTERACTING PROTEINS | THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE (US) | 2000-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244180-A1 | Substituted indole derivatives | IDO1, IDO2, HTR3A | NR4A2 2417/4885ALOX15 1774/4885F7 4133/4885 |
| US-20060160876-A1 | (6-Bromo-1,8-diethyl-1,3,4,9-tetrahydro-pyrano[3,4-b]indol-1-yl)-acetic acid ethyl ester; antineoplastic, anti-inflammatory, analgesic | IL6, OPRK1, PTGES3 | NR4A2 961/4885ALOX15 95/4885F7 3530/4885 |
| US-20060166947-A1 | Multiple myeloma treatments | BCL6, MCL1, BCL6B | NR4A2 3856/4885ALOX15 2217/4885F7 3293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.